Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-11-28, Stock:LLY, The news for the past five days is as follows:
2018-11-20: NEWS1: Corcept Initiates Phase III Study for Cushing's Syndrome.NEWS2: Corcept Initiates Phase III Study for Cushing's Syndrome.NEWS3: Corcept Initiates Phase III Study for Cushing's Syndrome.NEWS4: Analyzing Eli Lilly’s Stock Price and Financial Performance.NEWS5: See what the IHS Markit Score report has to say about Eli Lilly and Co..NEWS6: Eli Lilly (LLY) Gains As Market Dips: What You Should Know.NEWS7: Eli Lilly (LLY) Gains As Market Dips: What You Should Know.NEWS8: 3 Steady Healthcare Stocks to Hold During a Downturn.NEWS9: 3 Steady Healthcare Stocks to Hold During a Downturn.
2018-11-21: NEWS1: This Highly Rated Pharma Giant Is More Than Just A Diabetes Player.NEWS2: Eli Lilly's Stock May Drop 7% Short-Term.NEWS3: Is Franklin LibertyQ U.S. Equity ETF (FLQL) a Hot ETF Right Now?.NEWS4: Is Franklin LibertyQ U.S. Equity ETF (FLQL) a Hot ETF Right Now?.NEWS5: Is Franklin LibertyQ U.S. Equity ETF (FLQL) a Hot ETF Right Now?.NEWS6: See what the IHS Markit Score report has to say about Eli Lilly and Co..
2018-11-23: NEWS1: See what the IHS Markit Score report has to say about Eli Lilly and Co..
2018-11-26: NEWS1: Jardiance® Recommended as Preferred SGLT2 Inhibitor for Adults with Type 2 Diabetes and Established Cardiovascular Disease in American College of Cardiology Expert Consensus Decision Pathway.NEWS2: 4 Reasons Why Lilly is Up More Than 30% This Year So Far.NEWS3: 4 Reasons Why Lilly is Up More Than 30% This Year So Far.NEWS4: 4 Reasons Why Lilly is Up More Than 30% This Year So Far.
2018-11-27: NEWS1: Zafgen (ZFGN) Plunges as FDA Puts Hold on Diabetes Drug Trial.NEWS2: Lilly to Announce 2019 Financial Guidance, Highlight Late-Stage Pipeline Opportunities and Discuss Commercial Performance at Upcoming Investment Community Meeting.NEWS3: American College of Cardiology recommends empagliflozin as preferred SGLT2 inhibitor for adults with type 2 diabetes and established cardiovascular disease in new Expert Consensus Decision Pathway.

Answer: Rise